• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Archives of Pharmaceutical Sciences Ain Shams University
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 6 (2022)
Issue Issue 2
Issue Issue 1
Volume Volume 5 (2021)
Volume Volume 4 (2020)
Volume Volume 3 (2019)
Volume Volume 2 (2018)
Volume Volume 1 (2017)
Azzam, H., El-Derany, M., Wahdan, S., Faheim, R., Kamel, G., El-Demerdash Zaki, E. (2022). Taurine upregulated 1: Prognostic biomarker in breast cancer. Archives of Pharmaceutical Sciences Ain Shams University, 6(2), 264-273. doi: 10.21608/aps.2023.189963.1105
Hany Azzam; Marwa El-Derany; Sara Wahdan; Reham Faheim; Gouda Kamel; Ebtehal El-Demerdash Zaki. "Taurine upregulated 1: Prognostic biomarker in breast cancer". Archives of Pharmaceutical Sciences Ain Shams University, 6, 2, 2022, 264-273. doi: 10.21608/aps.2023.189963.1105
Azzam, H., El-Derany, M., Wahdan, S., Faheim, R., Kamel, G., El-Demerdash Zaki, E. (2022). 'Taurine upregulated 1: Prognostic biomarker in breast cancer', Archives of Pharmaceutical Sciences Ain Shams University, 6(2), pp. 264-273. doi: 10.21608/aps.2023.189963.1105
Azzam, H., El-Derany, M., Wahdan, S., Faheim, R., Kamel, G., El-Demerdash Zaki, E. Taurine upregulated 1: Prognostic biomarker in breast cancer. Archives of Pharmaceutical Sciences Ain Shams University, 2022; 6(2): 264-273. doi: 10.21608/aps.2023.189963.1105

Taurine upregulated 1: Prognostic biomarker in breast cancer

Article 8, Volume 6, Issue 2, December 2022, Page 264-273  XML PDF (597.65 K)
Document Type: Review Article
DOI: 10.21608/aps.2023.189963.1105
Authors
Hany Azzam1; Marwa El-Derany2; Sara Wahdan email 3; Reham Faheim4; Gouda Kamel5; Ebtehal El-Demerdash Zaki3
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt
2Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
3Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
4Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
5Department of Pharmacology and Toxicology, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
Abstract
The most common kind of cancer and the second leading cause of cancer mortality in women is breast cancer (BC). The most proven cause of mortality in BC patients comprises tumor metastasis and invasive development. Long noncoding RNAs are endangered by a number of crucial mechanisms involved in BC metastasis (lncRNAs). RNAs that are classified as lncRNAs are thought to be longer than 200 nucleotides in length. Literature has long shown that lncRNAs are promising therapeutic targets in BC as well as diagnostic and prognostic indicators. Only a few studies have, to our knowledge, described the bioenergetics of taurine upregulated 1 (TUG1). Human cancer has been linked to a new lncRNA called TUG1. TUG1 has drawn increasing interest in recent years and has been shown to express abnormally in several forms of cancer. Numerous research suggested that the development of tumefaction and cell metabolism may be favorably correlated with TUG1. As a result, we aimed to concentrate on recent developments in the primary molecular processes of TUG1 in cancer in this review. This includes its role in drug resistance, invasion, cell migration, apoptosis, and proliferation. Most recent investigations asserted that TUG was overexpressed in BC tissues and cell lines as compared to their normal counterparts. In order to better understand the critical impact of tamoxifen (TMX) resistance and improve quality of life (QOL), researchers are looking for an early diagnostic marker.
Keywords
Breast cancer; long noncoding RNAs; Taurine upregulated 1; Tamoxifen; Resistance
Statistics
Article View: 40
PDF Download: 29
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.